Loading organizations...
Based in Tel Aviv, Israel, Cassidy Bio is a biotechnology startup that develops artificial intelligence-driven genomic foundation models to design safer and more scalable gene editing therapies. The company utilizes machine learning algorithms trained on proprietary wet-lab data and population-scale genomics to predict optimal guides, enzymes, and delivery mechanisms for advanced genetic medicines. By shifting from traditional trial-and-error methods to predictive computational workflows, the platform targets developers working on complex diseases requiring CRISPR and base-editing solutions. The enterprise recently secured $8 million in seed funding led by Ahren Innovation Capital, with additional venture participation from corporate backers including AstraZeneca and Merck KGaA. The firm is also guided by scientific advisors from established industry entities such as Editas Medicine and Ultima Genomics. Cassidy Bio was founded in 2024 by Rom Kshuk, Ayal Hendel, and Yaniv Shmueli.
Cassidy Bio has raised $8.0M across 1 funding round.
Cassidy Bio has raised $8.0M in total across 1 funding round.
Cassidy Bio has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Seed in November 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 20, 2025 | $8M Seed | Oliver Hedaux | 10D, AstraZeneca, Lool Ventures, Merck | Announced |
Cassidy Bio has raised $8.0M in total across 1 funding round.
Cassidy Bio's investors include Oliver Hedaux, 10D, AstraZeneca, lool ventures, Merck.
